<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-041779</identifier>
<setSpec>0001-7310</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Cutaneous marginal zone B-cell lymphoma treated with rituximab</dc:title>
<dc:description xml:lang="en">Marginal zone B-cell lymphoma (MZL) is probably the most frequent of the primary cutaneous B-cell lymphomas, which are entities with indolent behavior. Clinically, it appears in middle-aged patients as papules, nodules or erythematous plaques, solitary or multiple, on the trunk and proximal part of the limbs. The prognosis is excellent despite frequent cutaneous recurrences. We present the case of a 40-year-old male who, after having several recurrences of MZL over a ten-year period, was treated with rituximab for multiple skin lesions. The patient showed full remission after four weeks of treatment, and developed cytokine-release syndrome after the first infusion of the drug</dc:description>
<dc:creator>García-Díez, Amaro</dc:creator>
<dc:creator>Pedraz, Javier</dc:creator>
<dc:creator>Fraga, Javier</dc:creator>
<dc:creator>Fernández-Herrera, Jesús</dc:creator>
<dc:creator>Delgado, Yolanda</dc:creator>
<dc:creator>Aragüés, Maximiliano</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El linfoma de células B de la zona marginal (LCBZM) es probablemente el más frecuente de los linfomas cutáneos primarios de células B, que son entidades de comportamiento indolente. Clínicamente aparece en pacientes de edad media en forma de pápulas, nódulos o placas eritematosas, solitarias o múltiples, en tronco y parte proximal de extremidades. El pronóstico es excelente a pesar de las frecuentes recurrencias cutáneas. Se presenta el caso de un varón de 40 años que, tras presentar varias recidivas de un LCBZM durante 10 años, fue tratado con rituximab por presentar múltiples lesiones cutáneas. El paciente presentó una remisión completa después de 4 semanas de tratamiento y desarrolló un síndrome de liberación de citocinas después de la primera infusión del medicamento</dc:description>
<dc:source>Actas Dermosifiliogr;96(9): 593-597, nov. 2005. ilus</dc:source>
<dc:identifier>ibc-041779</dc:identifier>
<dc:title xml:lang="es">Linfoma cutáneo de células B de la zona marginal tratado con rituximab</dc:title>
<dc:subject>^d29031^s22057</dc:subject>
<dc:subject>^d29014^s22067</dc:subject>
<dc:subject>^d24339^s22045</dc:subject>
<dc:subject>^d29031^s22016</dc:subject>
<dc:subject>^d28903^s22073</dc:subject>
<dc:subject>^d22921^s22045</dc:subject>
<dc:subject>^d13259^s22016</dc:subject>
<dc:subject>^d8398^s22016</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d32850^s22073</dc:subject>
<dc:subject>^d12428</dc:subject>
<dc:subject>^d29014^s22016</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d13259^s22067</dc:subject>
<dc:subject>^d8398^s22012</dc:subject>
<dc:subject>^d8398^s22067</dc:subject>
<dc:type>article</dc:type>
<dc:date>200511</dc:date>
</metadata>
</record>
</ibecs-document>
